Product/Composition:- | Asenapine Sublingual Tablets |
---|---|
Strength:- | 5 mg, 10 mg |
Form:- | Sublingual Tablets |
Reference Brands:- | Saphris®(US); Sycrest® (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Asenapine blocks dopamine D2 and serotonin 5-HT2A receptors, helping manage symptoms of schizophrenia and bipolar I disorder. Its sublingual delivery allows rapid absorption, making it effective for acute manic or mixed episodes, especially in patients needing fast symptom relief or with difficulty swallowing oral tablets.
Asenapine sublingual tablets are FDA-approved in the U.S. for treating schizophrenia and bipolar I disorder (acute manic or mixed episodes) in adults and pediatric patients. In the EU, they are approved under national procedures for similar indications. Regulatory compliance requires GMP-certified manufacturing, validated sublingual bioavailability data, and robust clinical safety profiles addressing risks such as oral numbness, extrapyramidal symptoms, and metabolic effects. U.S. regulations mandate boxed warnings for elderly patients with dementia-related psychosis. EU approval includes Risk Management Plans (RMPs) and pharmacovigilance systems. For dossier-ready Asenapine sublingual tablets, visit Pharmatradz.com — your B2B pharma sourcing expert.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications